Cargando…

BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma

Although much progress has been made in the treatment of multiple myeloma, the majority of patients fail to be cured and require numerous lines of therapy. Inhibitors of the BCL2 family represent an exciting new class of drugs with a novel mechanism of action that are likely to have activity as sing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Vikas A, Ackley, James, Kaufman, Jonathan L, Boise, Lawrence H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7965688/ https://www.ncbi.nlm.nih.gov/pubmed/33737856 http://dx.doi.org/10.2147/BLCTT.S245191

Ejemplares similares

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
por: Deng, Jiusheng, et al.
Publicado: (2016)

Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
por: Kaufman, Jonathan L., et al.
Publicado: (2021)

Acquisition of a Multidrug Resistant Phenotype with a Proteasome Inhibitor in Multiple Myeloma
por: Gutman, Delia, et al.
Publicado: (2009)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
por: Bajpai, R, et al.
Publicado: (2015)

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.
por: Sánchez, Cristina De Ramón, et al.
Publicado: (2023)

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2021)

Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells
por: Grad, Jennifer M., et al.
Publicado: (2001)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
por: Cao, Qiang, et al.
Publicado: (2023)

β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma
por: Nair, Remya, et al.
Publicado: (2022)

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
por: Schmidt, Timothy M., et al.
Publicado: (2019)

Dimethylarsinothioyl Glutathione as a Metabolite in Human Multiple Myeloma Cell Lines upon Exposure to Darinaparsin
por: Yehiayan, Lucy, et al.
Publicado: (2014)

Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström Macroglobulinemia
por: Gaudette, Brian T., et al.
Publicado: (2015)

MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma
por: Wang, Dongxue, et al.
Publicado: (2017)

New Treatment Strategies Making an Impact in Multiple Myeloma
por: Gleason, Charise, et al.
Publicado: (2017)

Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma
por: Slomp, Anne, et al.
Publicado: (2018)

Alterations in Glutathione Levels and Apoptotic Regulators Are Associated with Acquisition of Arsenic Trioxide Resistance in Multiple Myeloma
por: Matulis, Shannon M., et al.
Publicado: (2012)

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy
por: Robinson, M. Hope, et al.
Publicado: (2023)

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
por: Ramakrishnan, Vijay G., et al.
Publicado: (2019)

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
por: Schneller, Anja, et al.
Publicado: (2021)

A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors
por: Raimondi, Vincenzo, et al.
Publicado: (2022)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
por: Bajpai, Richa, et al.
Publicado: (2020)

Expression and Clinical Significance of BCL2 Interacting Protein 3 Like in Multiple Myeloma
por: Li, Ruolin, et al.
Publicado: (2021)

A Rare Case of BCL2-Positive Multiple Myeloma Complicated with Follicular Lymphoma
por: Tsutsumi, Yutaka, et al.
Publicado: (2022)

Game of Bones: How Myeloma Manipulates Its Microenvironment
por: Moser-Katz, Tyler, et al.
Publicado: (2021)

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation
por: Shah, Shardule P., et al.
Publicado: (2016)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1
por: Zhang, Z, et al.
Publicado: (2013)

mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation
por: Osada, Naoki, et al.
Publicado: (2021)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization
por: Li, Yixiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_au31vundfug2ceeqc9kqtcf0ea